VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 10, 2009) - Advanced Proteome Therapeutics Corporation (the "Corporation") (TSX VENTURE: APC) is pleased to announce that Kenneth C. Phillippe has accepted the position of Chief Financial Officer of the Corporation, effective immediately. Mr. Phillippe will assume the position of Chief Financial Officer from Alexander (Allen) Krantz, who has served as Chief Financial Officer since October 23, 2006. Mr. Krantz will continue to act as President, Chief Executive Officer and Secretary of the Corporation.
Mr. Phillippe is a Chartered Accountant with over 25 years experience working with public companies in the capacities of director, officer, financial advisor or consultant. He obtained a Bachelor of Commerce degree from the University of British Columbia in 1976 and his professional accounting designation in 1981. In the past Mr. Phillippe has served as a director and officer of Urodynamix Technologies Ltd., a Vancouver-based medical device company; chief financial officer of Columbia Goldfields Ltd., a junior gold mining company; Secretary, Treasurer, Chief Financial Officer and Principal Accounting Officer of Amazon Goldsands Ltd. and Constitution Mining Corp. Mr. Phillippe currently serves as Chief Financial Officer of Exchequer Resource Corp. and Chief Financial Officer and Secretary of Bold Ventures Inc.
Alexander Krantz, President, stated that "we are delighted to have Ken Phillippe assume the role of CFO in light of his vast accounting experience and expertise".
APC's primary corporate mission is to apply its proprietary drug delivery and drug redevelopment technologies to produce new, improved versions of therapeutic proteins and pioneer the emerging field of protein-site targeting. The market for diagnostics and therapeutic proteins and peptides is expected to surpass more than 50 Billion USD by the year 2010 and is the fastest growing segment of the pharmaceutical market. Future growth however depends largely on the industry overcoming a number of hurdles, including drug delivery challenges and the need for homogeneous conjugates that APC is attempting to address.
ON BEHALF OF THE BOARD
Alexander (Allen) Krantz, President and Chief Executive Officer
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.